ArticleScientific reports2026
Network analysis of serotonin CNVs shows biological convergence from genetic heterogeneity and discriminates between autism and developmental delay.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Differentiating autism spectrum disorder (ASD) from developmental delay (DD) is critical for guiding early intervention, but overlapping features and shared biological mechanisms pose challenges. This study investigates whether copy number variations (CNVs) affecting serotonergic genes carry sufficient information to distinguish between these neurodevelopmental disorders (NDDs). Using network mapping and machine learning, we applied gene ontology (GO) terms related to serotonergic systems to filter CNVs and construct networks modeling genetic and biological variation in ASD and DD. We identified hub nodes and subnetworks reflecting distinct patterns in gene and GO term interactions. ASD networks analysis yielded six genetic clusters, five of which remarkably contained genes specifically linked to serotonergic receptor mechanisms. In contrast, DD networks exhibited greater genetic homogeneity, with just two clusters sharing serotonergic mechanisms. Random Forest classifiers using serotonergic gene features achieved an average prediction accuracy of 85.6%, increasing to 88.6% when combined with dopaminergic dosage features, consistent with the two systems capturing partially non-overlapping biological signal. GO-based features yielded comparable accuracy with fewer inputs, emphasizing their efficiency. These findings demonstrate that different genetic alterations may be associated with disruption of shared biological pathways, each leaving a distinct signature tied to clinical diagnoses. Importantly, although genetic heterogeneity is observed in ASD, we found a homogeneity of serotonergic biological terms, suggesting convergence of mechanisms, which was distinct for each condition. Together, these results suggest that serotonergic CNVs carry discriminatory information for ASD vs. DD classification, and that combining serotonergic and dopaminergic features captures partially non-overlapping biological signal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.